Pfizer shares surged 8.6% to Rs 4,448.35 after announcing a marketing and supply agreement with Mylan Pharmaceuticals for Ativan and Pacitane. The five-year deal aims to enhance distribution and in-clinic presence. Despite the jump, Pfizer's stock has declined 18.29% YTD.